Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.57 |
| ▸ | AHR | P35869 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20449226 | 0.80 | MAP3K14 (0.49) | MAP3K14HTR1ACYP2D6SLC6A4MAOB | |
| SCHEMBL12316538 | 0.80 | MAP3K14 (0.57) | MAP3K14HTR1ACYP2D6SLC6A4 | |
| SCHEMBL20449228 | 0.80 | MAP3K14 (0.49) | MAP3K14HTR1ACYP2D6SLC6A4MAOB | |
| SCHEMBL12316643 | 0.73 | MAP3K14 (0.49) | MAP3K14PTGDR2 | |
| SCHEMBL12316626 | 0.73 | MAP3K14 (0.49) | MAP3K14PTGDR2 | |
| SCHEMBL12316632 | 0.73 | MAP3K14 (0.49) | MAP3K14SMN1; SMN2 | |
| SCHEMBL24393413 | 0.72 | MAP3K14 (0.75) | MAP3K14AHRHTR1ACYP2D6SLC6A4 | |
| SCHEMBL1271967 | 0.72 | MAP3K14 (0.51) | MAP3K14AHRHTR1ACYP2D6SLC6A4 | |
| SCHEMBL12501454 | 0.72 | MAP3K14 (0.65) | MAP3K14AHRHTR1ACYP2D6SLC6A4 | |
| SCHEMBL16397491 | 0.72 | MAP3K14 (0.75) | MAP3K14AHRHTR1ACYP2D6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | SLC29A1, SLC29A2, SLC43A3 | MAP3K14 3794/4885AHR 2672/4885HTR1A 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.